Your job-based insurance cut GLP-1 coverage. Here are some options

GLP-1 weight-loss medications like Wegovy and Ozempic are being removed from many employer-sponsored insurance plans, leaving workers to navigate new costs and options. Coverage from Inc.com and USA Today notes that 31 percent of workers would switch jobs for GLP-1 coverage, suggesting employers are starting to notice the retention risk. Benefits and Pensions Monitor questions what three years of GLP-1 claims data actually changed, implying insurers may be reassessing cost-effectiveness. Ideastream and AOL.com report insurers are pulling back on payments for weight-loss drugs, citing rising expenses and uncertain long-term outcomes. The contradiction is clear: demand for these drugs is high among employees, yet insurers and employers are restricting access to control costs.

The evidence shows a growing divide between employee expectations and employer benefits strategy. Multiple outlets report insurers are scaling back coverage, while workers are increasingly willing to leave their jobs over access to GLP-1 medications. The Benefits and Pensions Monitor's inquiry into actual claims outcomes suggests there may be limited data supporting continued broad coverage, adding pressure to the debate.

What comes next is unclear. Coverage does not yet specify whether employers will reverse course, offer supplemental plans, or shift costs to employees. The tension between employee demand and insurer caution leaves many workers navigating gaps in coverage while employers balance budgets and retention.